Overview

Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate
Vinblastine
Vinorelbine